

Datasheet for ABIN6138173 **anti-CD36 antibody (AA 30-270)**



[Go to Product page](#)

3 Images

Overview

Quantity:	100 µL
Target:	CD36
Binding Specificity:	AA 30-270
Reactivity:	Human
Host:	Rabbit
Clonality:	Polyclonal
Conjugate:	This CD36 antibody is un-conjugated
Application:	Western Blotting (WB)

Product Details

Immunogen:	Recombinant fusion protein containing a sequence corresponding to amino acids 30-270 of human CD36/SR-B3 (NP_001120916.1).
Sequence:	GDLLIQKTIK KQVVLEEGI AFKNWVKGT EVYRQFWIFD VQNPQEVMMN SSNIQVKQRG PYTYRVRFLA KENVTDQDAED NTVSFLQPNG AIFEPSLSVG TEADNFTVLN LAVAAASHIY QNQFVQMILN SLINKSKSSM FQVRTLRELL WGYRDPFLSL VPYPVTTTVG LFYPYNNTAD GVIYKVFNGKD NISKVAIDT YKGKRNLISYW ESHCDMINGT DAASFPPFVE KSQVLQFFSS D
Isotype:	IgG
Cross-Reactivity:	Human, Mouse, Rat
Characteristics:	Polyclonal Antibodies
Purification:	Affinity purification

Target Details

Target:	CD36
Alternative Name:	CD36 (CD36 Products)
Background:	<p>The protein encoded by this gene is the fourth major glycoprotein of the platelet surface and serves as a receptor for thrombospondin in platelets and various cell lines. Since thrombospondins are widely distributed proteins involved in a variety of adhesive processes, this protein may have important functions as a cell adhesion molecule. It binds to collagen, thrombospondin, anionic phospholipids and oxidized LDL. It directly mediates cytoadherence of Plasmodium falciparum parasitized erythrocytes and it binds long chain fatty acids and may function in the transport and/or as a regulator of fatty acid transport. Mutations in this gene cause platelet glycoprotein deficiency. Multiple alternatively spliced transcript variants have been found for this</p> <p>gene.,BDPLT10,CHDS7,FAT,GP3B,GP4,GPIV,PASIV,SCARB3,CD36,Cancer,Endocrine & Metabolism,Lipid Metabolism,Immunology & Inflammation,CD markers,Stem Cells,Endothelial Progenitors,Hematopoietic Progenitors,Cardiovascular,Blood,Heart,Lipids,Cardiovascular diseases,Heart disease,CD36</p>
Molecular Weight:	32 kDa/46 kDa/48 kDa/53 kDa
Gene ID:	948
UniProt:	P16671
Pathways:	TLR Signaling , Peptide Hormone Metabolism , Response to Growth Hormone Stimulus , Activation of Innate immune Response , Cellular Response to Molecule of Bacterial Origin , Regulation of Lipid Metabolism by PPARalpha , Positive Regulation of Immune Effector Process , Production of Molecular Mediator of Immune Response , Hepatitis C , Toll-Like Receptors Cascades , Lipid Metabolism , S100 Proteins

Application Details

Application Notes:	WB,1:500 - 1:2000
Restrictions:	For Research Use only


Handling

Format:	Liquid
Buffer:	PBS with 0.02 % sodium azide,50 % glycerol, pH 7.3.
Preservative:	Sodium azide

Handling

Precaution of Use:	This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
Storage:	-20 °C
Storage Comment:	Store at -20°C. Avoid freeze / thaw cycles.

Images





Western Blotting

Image 1. Western blot analysis of extracts of THP-1 cells, using CD36/SR-B3 antibody (ABIN6132248, ABIN6138173, ABIN6138174 and ABIN6221473) at 1:810 dilution. THP-1 cells were treated by PMA/TPA (200 nM) at 37 °C for 15 minutes after serum-starvation overnight. Secondary antibody: HRP Goat Anti-Rabbit IgG (H+L) (ABIN1684268 and ABIN3020597) at 1:10000 dilution. Lysates/proteins: 25 µg per lane. Blocking buffer: 3 % nonfat dry milk in TBST. Detection: ECL Basic Kit (RM00020). Exposure time: 30s.

Western Blotting

Image 2. BCAA upregulate PPAR-α and PPAR-α targeted genes. (A to B) Adult mouse cardiac myocytes were treated with different concentrations of BCAA (0, 0.429 mM, 0.858 mM, 1.716 mM, 3.432 mM) for 12 h (n=6). (A) Expression of PGC1-α, PPAR-γ, PPAR-α in cardiomyocytes by western blotting. (B) Expression of Ppara in cardiomyocytes by real-time PCR. (C-J) Adult cardiac myocytes were treated with Vehicle (Con), GW6471, BCAA, BCAA+GW6471 for 12 h. (C and D) Expression of ACAA2, ACADM, CD36, CPT1B in cardiomyocytes by western blotting and real-time PCR (n=6). (E) OCR curve of adult cardiac myocytes treated with Vehicle (Con), GW6471, BCAA, BCAA+GW6471 were determined (n=5). (F) Basal respiration (G) ATP production (H) maximal respiration (I) basal respiration due to exogenous palmitate-BSA and (J) maximal respiration due





to exogenous palmitate-BSA were calculated according to instruction. N=5 per group. * P<0.05, ** P<0.01. Data were analyzed by one-way ANOVA, followed by a Bonferroni post-hoc test. All values are presented as mean \pm SEM. - figure provided by CiteAb. Source: PMID32373236

Western Blotting

Image 3. Western blot analysis of extracts of various cell lines, using CD36/SR-B3 antibody (ABIN6132248, ABIN6138173, ABIN6138174 and ABIN6221473) at 1:810 dilution. Secondary antibody: HRP Goat Anti-Rabbit IgG (H+L) (ABIN1684268 and ABIN3020597) at 1:10000 dilution. Lysates/proteins: 25 μ g per lane. Blocking buffer: 3 % nonfat dry milk in TBST. Detection: ECL Basic Kit (RM00020). Exposure time: 30s.